42 results
8-K
EX-10.1
EBS
Emergent Biosolutions Inc
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification
8-K
EX-10.1
EBS
Emergent Biosolutions Inc
17 May 23
Emergent’s Statement Regarding its Amended Credit Agreement
9:32pm
as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects … that any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct (after
8-K
EBS
Emergent Biosolutions Inc
15 May 23
Completion of Acquisition or Disposition of Assets
8:01am
of materiality applicable to the parties that differ from those applicable to investors. Investors should not rely on the representations, warranties
8-K
hnk4 su5hmjdyy
26 Sep 22
Completion of Acquisition or Disposition of Assets
5:05pm
8-K
dcfz69dg 8hvq71eh
18 May 22
Entry into a Material Definitive Agreement
5:13pm
8-K
EX-2
rvnsfespxey86
18 May 22
Entry into a Material Definitive Agreement
5:13pm
CORRESP
a27e2wzfq3 w9m25
30 Sep 21
Correspondence with SEC
12:00am
S-3ASR
EX-5.1
npboz2 vvn0y
9 Aug 21
Automatic shelf registration
12:00am
8-K
EX-10.2
ujr0ng2z 9v6snes
7 Aug 20
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
4:33pm
8-K
EX-10.2
5uef1w5fw3usw1txk
7 Aug 20
Emergent BioSolutions Announces Successful Completion of Offering of 3.875% Senior Unsecured Notes Due 2028
4:29pm
8-K
EX-10
1117n91z8yclc7z
15 Oct 18
Completion of Acquisition or Disposition of Assets
5:22pm
8-K
EX-2
s03iu e7zglq8lmm
15 Oct 18
Completion of Acquisition or Disposition of Assets
5:22pm